Merck submits Keytruda for bladder cancer

by | Feb 6, 2017 | | 0

Merck & Co is continuing on its quest to expand the approved uses of its immunotherapy Keytruda, filing the drug in the US for both first- and second-line use in bladder cancer.

Read More